Menotropins

Current US Menopur is a subcutaneous urinary menotropins product for developing multiple follicles and pregnancy in ovulatory women during an ART cycle. It is fertility medicine, not sexual-performance or hormone-optimization treatment.

tier S · libido · 50.6% vs 51.5% cumulative live birth in MEGASET-HR

verdict

Monitored ART trials support Menopur's current female indication and quantify pregnancy, live-birth, OHSS, and multiple-pregnancy outcomes. Historical male hMG plus hCG findings do not create a current Menopur male indication or regimen.

the core tension

Menopur has direct product-specific fertility evidence, but only inside monitored female ART. A small uncontrolled 1985 hMG-plus-hCG study in selected men is class-level history, not a modern male Menopur indication, product regimen, or sexual-wellness result.

what it is

Menotropins, also called hMG or human menopausal gonadotropin, are a biologic mixture rather than one small molecule. Reconstituted Menopur supplies 75 IU FSH activity and 75 IU LH activity per vial, and the label says hCG is detected.

what it does

In the labeled female ART context, FSH and LH activity stimulate follicular growth and maturation. A separate hCG trigger follows adequate maturation. This biologic-activity description does not make Menopur interchangeable with recombinant FSH, purified FSH, LH alone, or another historical hMG product.

origin

FDA approved Menopur NDA 21-663 in 2004 for subcutaneous use in assisted reproduction. Current DailyMed labeling covers ovulatory women in an ART cycle and does not label the product for men, libido, hypogonadism, or hormone replacement.

does it work

The label trial and MEGASET-HR support controlled ovarian stimulation and pregnancy outcomes in monitored ART populations. MEGASET-HR found noninferior ongoing pregnancy and similar cumulative live birth in selected high responders, with protocol-dependent OHSS differences.

key facts

• molecular formula: not applicable to a biologic mixture
• molecular weight: no single molecular weight for the biologic mixture
• amino acids: not one defined peptide sequence
• half-life: 11 to 13 h for FSH activity after multiple SC or IM exposure in suppressed women
• type: urine-derived gonadotropin biologic mixture with FSH and LH activity
• CAS: 61489-71-2
• 373 women randomized to Menopur in the pivotal label study
• 620 women randomized in MEGASET-HR
• 21 men in the historical staged hCG and hMG study

frequently asked questions

What is Menopur approved for?

The current US product is approved for developing multiple follicles and pregnancy in ovulatory women participating in assisted reproductive technology.

Is Menopur approved for men?

No. Historical male hMG findings are not proof of a current Menopur male indication. The current US label is for women in ART.

Is menotropins one defined molecule?

No. It is a biologic mixture described by gonadotropin activity, so the page does not invent one molecular formula or molecular weight.

Why is monitoring central?

Follicular response, OHSS, ovarian enlargement, torsion, and multi-fetal pregnancy require experienced infertility care with ultrasound and or estradiol monitoring.

What is the measured human half-life?

The label reports an FSH elimination half-life of 11 to 13 hours after multiple subcutaneous or intramuscular dosing in pituitary-suppressed healthy premenopausal women. It is not whole-mixture or male PK.

related peptides

• hcg: a separate trigger in female ART and inseparable co-therapy in the historical male study

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.